CAR Ts to compete in earlier lines with Breyanzi label expansion

A second CAR T cell therapy targeting CD19 moves into the second-line setting with FDA’s approval of an sBLA for Breyanzi lisocabtagene maraleucel, expanding the market for the cell therapy and raising questions about access to the expensive yet effective therapies in the larger indication.

Breyanzi from Bristol Myers Squibb Co. (NYSE:BMY) was approved for use after failure of first-line treatment for adults with large B cell lymphoma that is refractory to or relapses within 12 months. It’s also now approved for relapsed or refractory patients who are not candidates for hematopoietic stem cell transplant (HSCT) due to co-morbidities or age...